Atomized Neutrophil Membrane-coated MOF Nanoparticles for Direct Delivery of Dexamethasone for Severe Pneumonia
Background: Dexamethasone has proven life-saving in severe acute respiratory syndrome (SARS) and COVID-19 cases. However, its systemic administration is accompanied by serious side effects. Inhalation delivery of dexamethasone (Dex) faces challenges such as low lung deposition, br...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2025-01-01
|
| Series: | Frontiers in Bioscience-Landmark |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/FBL/30/1/10.31083/FBL26721 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586493870211072 |
|---|---|
| author | Yixiao Yang Lizhen Yan Han Zhang Chuanguang Xiao Kai Wang |
| author_facet | Yixiao Yang Lizhen Yan Han Zhang Chuanguang Xiao Kai Wang |
| author_sort | Yixiao Yang |
| collection | DOAJ |
| description | Background: Dexamethasone has proven life-saving in severe acute respiratory syndrome (SARS) and COVID-19 cases. However, its systemic administration is accompanied by serious side effects. Inhalation delivery of dexamethasone (Dex) faces challenges such as low lung deposition, brief residence in the respiratory tract, and the pulmonary mucus barrier, limiting its clinical use. Neutrophil cell membrane-derived nanovesicles, with their ability to specifically target hyper-activated immune cells and excellent mucus permeability, emerge as a promising carrier for pulmonary inhalation therapy. Methods: We designed a novel UiO66 metal-organic framework nanoparticle loaded with Dex and coated with neutrophil cell membranes (UiO66-Dex@NMP) for targeted therapy of severe pneumonia. This was achieved by loading Dex into UiO66 pores and subsequently coating with neutrophil membranes for functionalization. Results: Drug release experiments revealed UiO66-Dex@NMP to exhibit favorable sustained-release properties. Additionally, UiO66-Dex@NMP demonstrated excellent targeting capabilities both in vitro and in vivo. In a mouse model of lipopolysaccharide (LPS)-induced pneumonia, UiO66-Dex@NMP significantly reduced lung inflammation compared to both the control model and Dex administered via inhalation. Histopathological analysis further confirmed UiO66-Dex@NMP’s ability to alleviate lung tissue damage. Conclusions: UiO66-Dex@NMP represents a novel and safe inhaled delivery carrier for Dex, offering valuable insights into the clinical management of respiratory diseases, including severe pneumonia. |
| format | Article |
| id | doaj-art-252313fe40504f4e9766c714778c131c |
| institution | Kabale University |
| issn | 2768-6701 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Frontiers in Bioscience-Landmark |
| spelling | doaj-art-252313fe40504f4e9766c714778c131c2025-01-25T08:55:52ZengIMR PressFrontiers in Bioscience-Landmark2768-67012025-01-013012672110.31083/FBL26721S2768-6701(24)01580-6Atomized Neutrophil Membrane-coated MOF Nanoparticles for Direct Delivery of Dexamethasone for Severe PneumoniaYixiao Yang0Lizhen Yan1Han Zhang2Chuanguang Xiao3Kai Wang4Institute of Translational Medicine, Shanghai University, 200444 Shanghai, ChinaDepartment of Respiratory and Critical Care Medicine, Zibo Municipal Hospital, 255400 Zibo, Shandong, ChinaInstitute of Translational Medicine, Shanghai University, 200444 Shanghai, ChinaDepartment of Breast Thyroid Surgery, Zibo Central Hospital, 255036 Zibo, Shandong, ChinaInstitute of Translational Medicine, Shanghai University, 200444 Shanghai, ChinaBackground: Dexamethasone has proven life-saving in severe acute respiratory syndrome (SARS) and COVID-19 cases. However, its systemic administration is accompanied by serious side effects. Inhalation delivery of dexamethasone (Dex) faces challenges such as low lung deposition, brief residence in the respiratory tract, and the pulmonary mucus barrier, limiting its clinical use. Neutrophil cell membrane-derived nanovesicles, with their ability to specifically target hyper-activated immune cells and excellent mucus permeability, emerge as a promising carrier for pulmonary inhalation therapy. Methods: We designed a novel UiO66 metal-organic framework nanoparticle loaded with Dex and coated with neutrophil cell membranes (UiO66-Dex@NMP) for targeted therapy of severe pneumonia. This was achieved by loading Dex into UiO66 pores and subsequently coating with neutrophil membranes for functionalization. Results: Drug release experiments revealed UiO66-Dex@NMP to exhibit favorable sustained-release properties. Additionally, UiO66-Dex@NMP demonstrated excellent targeting capabilities both in vitro and in vivo. In a mouse model of lipopolysaccharide (LPS)-induced pneumonia, UiO66-Dex@NMP significantly reduced lung inflammation compared to both the control model and Dex administered via inhalation. Histopathological analysis further confirmed UiO66-Dex@NMP’s ability to alleviate lung tissue damage. Conclusions: UiO66-Dex@NMP represents a novel and safe inhaled delivery carrier for Dex, offering valuable insights into the clinical management of respiratory diseases, including severe pneumonia.https://www.imrpress.com/journal/FBL/30/1/10.31083/FBL26721dexamethasonemofneutrophil cell membraneinhaled deliverysevere pneumonia |
| spellingShingle | Yixiao Yang Lizhen Yan Han Zhang Chuanguang Xiao Kai Wang Atomized Neutrophil Membrane-coated MOF Nanoparticles for Direct Delivery of Dexamethasone for Severe Pneumonia Frontiers in Bioscience-Landmark dexamethasone mof neutrophil cell membrane inhaled delivery severe pneumonia |
| title | Atomized Neutrophil Membrane-coated MOF Nanoparticles for Direct Delivery of Dexamethasone for Severe Pneumonia |
| title_full | Atomized Neutrophil Membrane-coated MOF Nanoparticles for Direct Delivery of Dexamethasone for Severe Pneumonia |
| title_fullStr | Atomized Neutrophil Membrane-coated MOF Nanoparticles for Direct Delivery of Dexamethasone for Severe Pneumonia |
| title_full_unstemmed | Atomized Neutrophil Membrane-coated MOF Nanoparticles for Direct Delivery of Dexamethasone for Severe Pneumonia |
| title_short | Atomized Neutrophil Membrane-coated MOF Nanoparticles for Direct Delivery of Dexamethasone for Severe Pneumonia |
| title_sort | atomized neutrophil membrane coated mof nanoparticles for direct delivery of dexamethasone for severe pneumonia |
| topic | dexamethasone mof neutrophil cell membrane inhaled delivery severe pneumonia |
| url | https://www.imrpress.com/journal/FBL/30/1/10.31083/FBL26721 |
| work_keys_str_mv | AT yixiaoyang atomizedneutrophilmembranecoatedmofnanoparticlesfordirectdeliveryofdexamethasoneforseverepneumonia AT lizhenyan atomizedneutrophilmembranecoatedmofnanoparticlesfordirectdeliveryofdexamethasoneforseverepneumonia AT hanzhang atomizedneutrophilmembranecoatedmofnanoparticlesfordirectdeliveryofdexamethasoneforseverepneumonia AT chuanguangxiao atomizedneutrophilmembranecoatedmofnanoparticlesfordirectdeliveryofdexamethasoneforseverepneumonia AT kaiwang atomizedneutrophilmembranecoatedmofnanoparticlesfordirectdeliveryofdexamethasoneforseverepneumonia |